FDA Official Dr. Vinay Prasad Leaves Controversial Post

Dr. Vinay Prasad's Brief Tenure at the FDA Ends in Resignation

Dr. Vinay Prasad, a prominent figure known for his critical stance towards the U.S. Food and Drug Administration (FDA), has stepped down from his positions within the agency less than three months after joining. His departure marks the end of a short tenure that was marked by controversy and internal conflicts.

A spokesperson for the U.S. Department of Health and Human Services stated that Prasad chose to leave the FDA to avoid becoming a distraction during a time of significant activity under the Trump administration. He plans to return to California to focus more on his family. Prasad, a hematologist oncologist, was appointed as the head of the FDA’s Center for Biologics Evaluation and Research in May, which gave him oversight over vaccines and biologic medicines. He was also appointed as the FDA’s chief medical and scientific officer.

Prasad had previously been a vocal critic of the government's handling of the COVID-19 pandemic, including its vaccine policies. His resignation came amid mounting pressure from the White House, according to sources familiar with the situation. This pressure followed days of public criticism from Laura Loomer, a right-wing activist with close ties to President Donald Trump. Loomer accused Prasad of being a “progressive leftist saboteur” who was undermining the president’s FDA efforts.

Loomer highlighted Prasad’s past social media posts and podcast appearances, where she claimed he aligned himself with liberal politicians and expressed disdain for Trump. Her criticisms were echoed by figures such as former U.S. Senator Rick Santorum, who called Prasad “the man destroying @POTUS legacy for helping patients.” A Wall Street Journal opinion piece further criticized Prasad, labeling him a “Bernie Sanders acolyte in MAHA drag.”

Despite the controversies, Prasad had received support from FDA Commissioner Dr. Marty Makary, who praised him as an “impeccable scientist … one of the greatest scientific minds of our generation.” The HHS spokesperson expressed gratitude for Prasad’s service and the reforms he achieved during his time at the FDA.

Before joining the FDA, Prasad was known for his critiques of the agency’s drug approval processes. He notably opposed the approval of Sarepta’s drug Elevidys for Duchenne muscular dystrophy, arguing that there was insufficient evidence of its effectiveness. This month, the FDA requested that Sarepta halt shipments of the drug after a reported death in a young patient in Brazil. Just before Prasad’s resignation, the agency reversed its decision and allowed Sarepta to resume shipments for certain patients.

Additionally, Prasad faced criticism from former officials and vaccine experts after internal memos revealed that he overrode recommendations from FDA scientists regarding two new versions of the COVID-19 vaccines. The then-CDER director had initially recommended against broad use of the shots, but the FDA eventually approved the vaccines for older and immunocompromised individuals without advising their use for younger Americans without underlying conditions.

Prasad’s departure from the FDA highlights the complex interplay between scientific integrity and political pressures within regulatory agencies. As the agency continues to navigate these challenges, the impact of his brief tenure remains a subject of ongoing discussion.